CP
IONS icon

CenterBook Partners’s Ionis Pharmaceuticals IONS Stock Holding History

CenterBook Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.08M Sell
89,280
-61,632
-41% -$4.64M 0.35% 62
2026
Q1 		$11.3M Sell
150,912
-3,037
-2% -$240K 0.61% 33
2025
Q4 		$12.2M Buy
+153,949
New +$11.6M 0.6% 34

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

CenterBook Partners's IONS Position: Q2 2026 in Review

CenterBook Partners reduced its Ionis Pharmaceuticals (IONS) stake by 41% in Q2 2026, selling an estimated $4.64M and leaving 89,280 shares worth $7.08M. The position accounts for 0.35% of the portfolio, ranked #62.

CenterBook Partners first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.2M in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • CenterBook Partners held 89,280 shares of Ionis Pharmaceuticals worth $7.08M as of Q2 2026.
  • CenterBook Partners sold 61,632 Ionis Pharmaceuticals shares in Q2 2026, an estimated $4.64M.
  • Ionis Pharmaceuticals made up 0.35% of CenterBook Partners's portfolio in Q2 2026, its #62 holding.
  • CenterBook Partners first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • CenterBook Partners's Ionis Pharmaceuticals position peaked at $12.2M in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.